Index Pharma Q2’21: CONCLUDE About to Commence - Redeye

Redeye leaves its view on InDex Pharmaceuticals following the announcement of its Q2 report. The company’s pivotal phase III study will commence shortly, and we see an attractive entry-level into the share.

Länk till analysen i sin helhet: https://www.redeye.se/research/819472/index-pharma-q221-conclude-about-to-commence?utm_source=finwire&utm_medium=RSS